Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of recurrent endometrioid endometrial carcinoma: an overview.
van Wijk FH, van der Burg ME, Burger CW, Vergote I, van Doorn HC. van Wijk FH, et al. Among authors: van doorn hc, van der burg me. Int J Gynecol Cancer. 2009 Apr;19(3):314-20. doi: 10.1111/IGC.0b013e3181a7f71e. Int J Gynecol Cancer. 2009. PMID: 19407552 Review.
What is the role of dose-dense therapy?
van der Burg ME, van der Gaast A, Vergote I, Burger CW, van Doorn HC, de Wit R, Stoter G, Verweij J. van der Burg ME, et al. Among authors: van doorn hc, van der gaast a. Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:233-40. doi: 10.1111/j.1525-1438.2005.00432.x. Int J Gynecol Cancer. 2005. PMID: 16343238 Free article. Review.
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
van Wijk FH, Aapro MS, Bolis G, Chevallier B, van der Burg ME, Poveda A, de Oliveira CF, Tumolo S, Scotto di Palumbo V, Piccart M, Franchi M, Zanaboni F, Lacave AJ, Fontanelli R, Favalli G, Zola P, Guastalla JP, Rosso R, Marth C, Nooij M, Presti M, Scarabelli C, Splinter TA, Ploch E, Beex LV, ten Bokkel Huinink W, Forni M, Melpignano M, Blake P, Kerbrat P, Mendiola C, Cervantes A, Goupil A, Harper PG, Madronal C, Namer M, Scarfone G, Stoot JE, Teodorovic I, Coens C, Vergote I, Vermorken JB; European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. van Wijk FH, et al. Among authors: van der burg me. Ann Oncol. 2003 Mar;14(3):441-8. doi: 10.1093/annonc/mdg112. Ann Oncol. 2003. PMID: 12598351 Free article. Clinical Trial.
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.
Vencken PMLH, Kriege M, Hoogwerf D, Beugelink S, van der Burg MEL, Hooning MJ, Berns EM, Jager A, Collée M, Burger CW, Seynaeve C. Vencken PMLH, et al. Among authors: van der burg mel. Ann Oncol. 2011 Jun;22(6):1346-1352. doi: 10.1093/annonc/mdq628. Epub 2011 Jan 12. Ann Oncol. 2011. PMID: 21228333 Free article.
Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME, Onstenk W, Boere IA, Look M, Ottevanger PB, de Gooyer D, Kerkhofs LG, Valster FA, Ruit JB, van Reisen AG, Goey SH, van der Torren AM, ten Bokkel Huinink D, Kok TC, Verweij J, van Doorn HC. van der Burg ME, et al. Eur J Cancer. 2014 Oct;50(15):2592-601. doi: 10.1016/j.ejca.2014.07.015. Epub 2014 Aug 2. Eur J Cancer. 2014. PMID: 25096168 Clinical Trial.
151 results